GONAL-F® RFF 75 IU (follitropin alfa for injection)
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.

Sign-in
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

GONAL-F® RFF* 75 IU

Approved in 1997, GONAL-F® RFF* 75 IU was our original offering to induce follicular development and was the first r-hFSH in the US

Our original offering to induce follicular development1

 

GONAL-F RFF* (follitropin alfa for injection) is indicated for:

  • Induction of ovulation and pregnancy in the oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure
  • Development of multiple follicles in the ovulatory infertile women as part of an Assisted Reproductive Technology (ART) cycle. 
stats

With 25 years of trial and patient experience, GONAL-F is the #1 most prescribed r-hFSH in the U.S.2 It has helped bring over 3 million babies to life worldwide.3†

Clinical trial efficacy in OI and ART1

Ovulation induction (OI) study

Clinical trial

Study design

 

Induction of Ovulation was evaluated in a randomized, assessor-blind, multinational, multicenter, active-controlled trial in oligo-anovulatory infertile women. Women were randomized to either GONAL-F RFF* 75 IU (n=83), administered subcutaneously, or a comparator r-hFSH product. The use of insulin-sensitizing agents was allowed during the trial. The trial was designed to evaluate and compare mean ovulation rates in the first cycle of treatment. Results for GONAL-F RFF* 75 IU are presented in Table 3. Also presented in this table are secondary outcome results from cycle 1 through 3. The trial was not powered to demonstrate differences in any of the secondary outcomes.

 

Results with GONAL-F RFF* 75 IU

 

 

GONAL-F RFF* 75 IU (n=83)

 

Cycle

CumulativePercent Ovulation

Cumulativea Clinical Pregnancyd Rate

Cycle 1

72%b

28%c

Cycle 2

89%c

41%c

Cycle 3

92%c

45%c

 

aCumulative rates were determined per woman over cycles 1, 2, and 3.

bNoninferior to comparator r-hFSH based on a two-sided 95% confidence interval, intent-to-treat analysis.

cSecondary efficacy outcomes. The study was not powered to demonstrate differences in these outcomes.

dClinical pregnancy was defined as a pregnancy for which a fetal sac (with or without heart activity) was visualized by ultrasound on day 34-36 after hCG administration.

Adverse reactions

In a multiple cycle (a maximum of three cycles), assessor-blind, multinational, multicenter, active-comparator trial versus a r-hFSH comparator, a total of 83 oligo-anovulatory infertile women were randomized and underwent induction of ovulation with GONAL-F RFF* 75 IU. Adverse reactions occurring in at least 2.0% of women receiving GONAL-F RFF* 75 IU are listed in Table 1. The following common adverse reactions were reported at ≥2% in one OI clinical trial, Study 22240.

 

System Organ Class/Adverse Reactions

GONAL-F RFF* 75 IU [N=83a (176 treatment cyclesb)]nc (%)

Central and peripheral nervous system

Headache

22 (26.5%)

Gastrointestinal system

Abdominal pain

10 (12.0%)

Nausea

3 (3.6%)

Flatulence

3 (3.6%)

Diarrhea

3 (3.6%)

Reproductive, female

Ovarian hyperstimulation

6 (7.2%)

Ovarian cyst

3 (3.6%)

Application site

Injection site pain

4 (4.8%)

Injection site inflammation

2 (2.4%)

 

aTotal number of women treated with GONAL-F RFF* 75 IU. 

bUp to 3 cycles of therapy.

cNumber of women with the adverse reaction.

Assisted reproductive technology (ART) study

Clinical trial

Study design

 

The efficacy of GONAL-F RFF* 75 IU was evaluated in a randomized, assessor-blind, multinational, multicenter active-controlled trial in ovulatory, infertile women treated for one cycle with controlled ovarian stimulation as part of an ART [in vitro fertilization (IVF), or intracytoplasmic sperm injection (ICSI)] cycle. Women were randomized to either GONAL-F RFF* 75 IU (n=237), administered subcutaneously, or a comparator r-hFSH product. Randomization was stratified by insemination technique (IVF versus ICSI). All women received a GnRH agonist for pituitary down-regulation before receiving stimulation with r-hFSH. The primary endpoint was the mean number of fertilized oocytes the day after insemination. The initial doses of GONAL-F RFF* 75 IU were 150 International Units per day for women less than 35 years of age and 225 International Units per day for women 35 years of age and older. The maximal dose given for both age groups was 450 International Units per day. Treatment outcomes for GONAL-F RFF* 75 IU are summarized in Table 4.

 

Results with GONAL-F RFF* 75 IU

 

Trial Outcome

Value (n)

Mean number of 2PN oocytes per womana

 

6.3 (n=237)

 

Mean number of 2PN oocytes per woman receiving IVFb

 

6.1 (n=88)

 

Mean number of 2PN oocytes per woman receiving ICSIb

 

6.5 (n=132)

 

Clinical pregnancyc rate per attemptd

 

33.5% (218)

 

Clinical pregnancyc rate per embryo transferd

 

35.8% (204)

 

Mean treatment duration in days (range)d

 

9.7 [3-21] (230)

 

 

aNoninferior to comparator r-hFSH based on a two-sided 95% confidence interval, intent-to-treat analysis.

bSubgroup analyses. The trial was not powered to demonstrate differences in subgroups. 

cA clinical pregnancy was defined as a pregnancy during which a fetal sac (with or without heart activity) was visualized by ultrasound on day 35-42 after hCG administration. 

dSecondary efficacy outcomes. The trial was not powered to demonstrate differences in these outcomes. 

Adverse reactions

In a single cycle, assessor-blind, multinational, multicenter, active-comparator trial versus a r-hFSH comparator, a total of 237 normal ovulatory infertile women were randomized and received GONAL-F RFF* 75 IU as part of an ART [in vitro fertilization (IVF) or intracytoplasmic sperm injection cycle (ICSI)] cycle. All women received pituitary down-regulation with gonadotropin releasing hormone (GnRH) agonist before stimulation. Adverse Reactions occurring in at least 2.0% of women are listed in Table 2. 

 

System Organ Class/Adverse Reactions GONAL-F RFF* 75 IU
(N=237a)
nb(%)

Gastrointestinal system

Abdominal pain

55 (23.2%)

Nausea

19 (8.0%)

Body as a whole-general

Abdomen enlarged

33 (13.9%)

Central and peripheral nervous system

Headache

44 (18.6%)

Application site disorders

Injection site bruising

23 (9.7%)

Injection site pain

13 (5.5%)

Injection site inflammation

10 (4.2%)

Injection site reaction

10 (4.2%)

Application site edema

6 (2.5%)

Reproductive, female

Ovarian hyperstimulation

11 (4.6%)

 

aTotal number of women treated with GONAL-F RFF* 75 IU. 

bNumber of women with the adverse reaction.

r-hFSH = recombinant human follicle-stimulating hormone.
*RFF = revised formulation female.

Prescribing information

 

 English

 Spanish

 Mandarin

Instructions for use

 

 English

 Spanish

 Mandarin

Injection training videos

Review simple steps for medication administration

Watch now

Patient medication savings

Financial support for eligible patients

See programs

QUESTIONS OR REQUESTS?

An EMD Serono fertility partnership manager can help answer questions or provide a demo for injection training.

Contact a rep

References

1. GONAL-F RFF* 75 IU (follitropin alfa for injection)  [Prescribing Information]. Rockland, MA: EMD Serono, Inc.; 2018.

2. Data on file. IQVIA Market Data Analysis. December 2020.

3. Longobardi S, Seidler A, Martins J, et al. An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses. Expert Opin Drug Deliv. 2019;16(9):1003-1014.

IMPORTANT RISK INFORMATION & INDICATIONS AND USAGE

Important Risk Information for GONAL-F® RFF 75 IU (follitropin alfa for injection)

Contraindications:
GONAL-F® RFF is contraindicated in women who exhibit: 

  • Prior hypersensitivity to recombinant FSH products or one of their excipients. Reactions have included anaphylaxis.
  • High levels of FSH indicating primary gonadal failure
  • The presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders)
  • Sex hormone dependent tumors of the reproductive tract and accessory organs
  • Tumors of the pituitary gland or hypothalamus
  • Abnormal uterine bleeding of undetermined origin
  • Ovarian cyst or enlargement of undetermined origin

 

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions and Anaphylaxis
In the post-marketing experience, serious systemic hypersensitivity reactions, including anaphylaxis, have been reported with use of GONAL-F and GONAL-F RFF.  Symptoms have included dyspnea, facial edema, pruritus, and urticaria.  If an anaphylactic or other serious allergic reaction occurs, initiate appropriate therapy including supportive measures if cardiovascular instability and/or respiratory compromise occur, and discontinue further use.

Overstimulation of the Ovary During FSH Therapy:

  • If serious ovarian hyperstimulation syndrome (OHSS) occurs, stop gonadotropins, including GONAL-F RFF 75 IU and hCG, and consider whether the woman needs to be hospitalized. 
  • OHSS increases the risk of injury to the ovary.  Avoid pelvic examination or intercourse, as these may cause rupture of an ovarian cyst, which may result in hemoperitoneum. 
  • A physician experienced in the management of this syndrome, or who is experienced in the management of fluid and electrolyte imbalances should be consulted.
  • OHSS occurred in 6 of 83 (7.2%) GONAL-F RFF 75 IU treated women in an induction of ovulation trial; none were classified as severe.  In an ART trial, OHSS occurred in 11 of 237 (4.6%) GONAL-F RFF 75 IU treated women and 1 (0.42%) was classified as severe.

 

Pulmonary and Vascular Complications: 

Serious pulmonary conditions (for example, atelectasis, acute respiratory distress syndrome and exacerbation of asthma) have been reported in women treated with gonadotropins, including GONAL-F RFF 75 IU.  In addition, thromboembolic events both in association with, and separate from OHSS have been reported in women treated with gonadotropins, including GONAL-F RFF 75 IU.  Intravascular thrombosis and embolism, which may originate in venous or arterial vessels, can result in reduced blood flow to critical organs or the extremities.  Women with generally recognized risk factors for thrombosis, such as personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins.  Sequelae of such events have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarctions.  In rare cases, pulmonary complications and/or thromboembolic events have resulted in death.  In women with recognized risk factors, the benefits of ovulation induction and Assisted Reproductive Technology (ART) need to be weighed against the risks.  It should be noted that pregnancy also carries an increased risk of thrombosis. 

Ovarian Torsion
Ovarian torsion has been reported after treatment with gonadotropins, including GONAL-F RFF 75 IU.  This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries.  Early diagnosis and immediate detorsion limit damage to the ovary due to reduced blood supply.

Abnormal Ovarian Enlargement
In order to minimize the hazards associated with abnormal ovarian enlargement that may occur with GONAL-F RFF 75 IU therapy, individualize treatment and use the lowest effective dose.  Use of ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels is important to minimize the risk of ovarian stimulation. If the ovaries are abnormally enlarged on the last day of GONAL-F RFF 75 IU therapy, do not administer hCG in order to reduce the chance of developing OHSS.  Prohibit intercourse for women with significant ovarian enlargement after ovulation because of the danger of hemoperitoneum resulting from rupture of ovarian cysts.

Multi-fetal Gestation and Birth
Multi-fetal gestation and births have been reported with all gonadotropin therapy, including therapy with GONAL-F RFF 75 IU.  In a trial of induction of ovulation, 20% of live births were multiple births in women receiving GONAL-F RFF 75 IU over three treatment cycles. 

In an ART trial, 35.1% of live births were multiple births in women receiving GONAL-F RFF 75 IU.  The rate of multiple births is dependent on the number of embryos transferred.  Advise the woman and her partner of the potential risk of multi-fetal gestation and birth before beginning therapy with GONAL-F RFF 75 IU.

Embryofetal Toxicity
The incidence of congenital malformations (birth defects) after some Assisted Reproductive Technology [(ART) specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception.  This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI.  There is no evidence that the use of gonadotropins during IVF or ICSI is associated with an increased risk of congenital malformations.

Ectopic Pregnancy
Since infertile women undergoing ART often have tubal abnormalities, the incidence of ectopic pregnancy may be increased in women who become pregnant as a result of ART.  Advise women who become pregnant following ART and have: abdominal/pelvic pain (particularly on one side); shoulder, neck or rectal pain; and nausea and vomiting to seek immediate medical attention.  Confirm the presence of an intrauterine pregnancy early by β-hCG testing and transvaginal ultrasound.

Spontaneous Abortion
The risk of spontaneous abortion (miscarriage) is increased with gonadotropin products, including GONAL-F RFF 75 IU.  However, causality has not been established.  The increased risk may be a factor of the underlying infertility.

Ovarian Neoplasms
There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have had multiple drug therapy for controlled ovarian stimulation, however, a causal relationship has not been established.

Laboratory Tests
In most instances, treatment of women with GONAL-F RFF 75 IU results only in follicular recruitment and development.  In the absence of an endogenous LH surge, hCG is given to trigger ovulation when monitoring of the patient indicates that sufficient follicular development has occurred.  This may be estimated by ultrasound alone or in combination with measurement of serum estradiol concentrations.  The combination of both ultrasound and serum estradiol measurement are useful for monitoring follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement and minimizing the risk of the Ovarian Hyperstimulation Syndrome and multiple gestation.  

 

ADVERSE REACTIONS:

The most common adverse reactions (≥2%) in ovulation induction (OI) include: headache, abdominal pain, ovarian hyperstimulation, injection site pain, nausea, flatulence, diarrhea, ovarian cyst, and injection site inflammation. The most common adverse reactions (≥2%) in ART include: abdominal pain, headache, abdomen enlarged, injection site bruising, nausea, injection site pain, ovarian hyperstimulation, injection site inflammation, injection site reaction, and injection site edema.
 

SPECIFIC POPULATIONS:

Pregnancy: GONAL-F RFF 75 IU is not indicated in pregnant women. There is no human data that the use of gonadotropins (including GONAL-F RFF 75 IU), alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations. The risk of spontaneous abortion (miscarriage) is increased in women who have used gonadotropins products (including GONAL-F RFF 75 IU) to achieve pregnancy.

Lactation: There are no data on the presence of GONAL-F RFF 75 IU in human milk, the effects on the breastfed infant, or the effects on milk production.  Because the secretion of prolactin during lactation can result in inadequate response to ovarian stimulation, advise women not to breast feed during treatment with GONAL-F RFF 75 IU.

Females and Males of Reproductive Potential:  Because GONAL-F RFF 75 IU is not indicated in pregnant women, verify a negative pregnancy test before administering GONAL-F RFF 75 IU to a woman.

Pediatric use: Safety and effectiveness in pediatric patients have not been established.

Geriatric use: Safety and effectiveness of GONAL-F RFF in postmenopausal women have not been established and it is not indicated in this population.

 

PATIENT COUNSELING INFORMATION:

Instruct women on the correct usage and dosing of GONAL-F RFF 75 IU.  Instruct women to reconstitute one or more vials of GONAL-F RFF 75 IU using 1 mL sterile diluent and the 18G 1-1/2” pink mixing needle provided.  Instruct women to safely remove mixing needle and replace with 29G ½” needle for injection.  Caution women not to change the dosage or the schedule of administration unless she is told to do so by her healthcare provider. 

Prior to beginning therapy with GONAL-F RFF 75 IU, inform women about the time commitment and monitoring procedures necessary for treatment.

Inform the woman that if she misses or forgets to take a dose of GONAL-F RFF 75 IU, she should not double the next dose and should call her healthcare provider for further dosing instructions.

For more information, please see the full Prescribing Information and Instructions for Use for GONAL-F RFF 75 IU.

Indications and Usage:

  • Induction of ovulation and pregnancy in the oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure
  • Development of multiple follicles in ovulatory infertile women as part of an Assisted Reproductive Technology (ART) cycle.

 

RFF = revised formulation female.

 

IMPORTANT RISK INFORMATION & INDICATIONS AND USAGE

Important Risk Information for GONAL-F® RFF 75 IU (follitropin alfa for injection)

Contraindications:
GONAL-F® RFF is contraindicated in women who exhibit: 

  • Prior hypersensitivity to recombinant FSH products or one of their excipients. Reactions have included anaphylaxis.
  • High levels of FSH indicating primary gonadal failure
  • The presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders)
  • Sex hormone dependent tumors of the reproductive tract and accessory organs
  • Tumors of the pituitary gland or hypothalamus
  • Abnormal uterine bleeding of undetermined origin
  • Ovarian cyst or enlargement of undetermined origin

 

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions and Anaphylaxis
In the post-marketing experience, serious systemic hypersensitivity reactions, including anaphylaxis, have been reported with use of GONAL-F and GONAL-F RFF.  Symptoms have included dyspnea, facial edema, pruritus, and urticaria.  If an anaphylactic or other serious allergic reaction occurs, initiate appropriate therapy including supportive measures if cardiovascular instability and/or respiratory compromise occur, and discontinue further use.

Overstimulation of the Ovary During FSH Therapy:

  • If serious ovarian hyperstimulation syndrome (OHSS) occurs, stop gonadotropins, including GONAL-F RFF 75 IU and hCG, and consider whether the woman needs to be hospitalized. 
  • OHSS increases the risk of injury to the ovary.  Avoid pelvic examination or intercourse, as these may cause rupture of an ovarian cyst, which may result in hemoperitoneum. 
  • A physician experienced in the management of this syndrome, or who is experienced in the management of fluid and electrolyte imbalances should be consulted.
  • OHSS occurred in 6 of 83 (7.2%) GONAL-F RFF 75 IU treated women in an induction of ovulation trial; none were classified as severe.  In an ART trial, OHSS occurred in 11 of 237 (4.6%) GONAL-F RFF 75 IU treated women and 1 (0.42%) was classified as severe.

 

Pulmonary and Vascular Complications: 

Serious pulmonary conditions (for example, atelectasis, acute respiratory distress syndrome and exacerbation of asthma) have been reported in women treated with gonadotropins, including GONAL-F RFF 75 IU.  In addition, thromboembolic events both in association with, and separate from OHSS have been reported in women treated with gonadotropins, including GONAL-F RFF 75 IU.  Intravascular thrombosis and embolism, which may originate in venous or arterial vessels, can result in reduced blood flow to critical organs or the extremities.  Women with generally recognized risk factors for thrombosis, such as personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins.  Sequelae of such events have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarctions.  In rare cases, pulmonary complications and/or thromboembolic events have resulted in death.  In women with recognized risk factors, the benefits of ovulation induction and Assisted Reproductive Technology (ART) need to be weighed against the risks.  It should be noted that pregnancy also carries an increased risk of thrombosis. 

Ovarian Torsion
Ovarian torsion has been reported after treatment with gonadotropins, including GONAL-F RFF 75 IU.  This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries.  Early diagnosis and immediate detorsion limit damage to the ovary due to reduced blood supply.

Abnormal Ovarian Enlargement
In order to minimize the hazards associated with abnormal ovarian enlargement that may occur with GONAL-F RFF 75 IU therapy, individualize treatment and use the lowest effective dose.  Use of ultrasound monitoring of ovarian response and/or measurement of serum estradiol levels is important to minimize the risk of ovarian stimulation. If the ovaries are abnormally enlarged on the last day of GONAL-F RFF 75 IU therapy, do not administer hCG in order to reduce the chance of developing OHSS.  Prohibit intercourse for women with significant ovarian enlargement after ovulation because of the danger of hemoperitoneum resulting from rupture of ovarian cysts.

Multi-fetal Gestation and Birth
Multi-fetal gestation and births have been reported with all gonadotropin therapy, including therapy with GONAL-F RFF 75 IU.  In a trial of induction of ovulation, 20% of live births were multiple births in women receiving GONAL-F RFF 75 IU over three treatment cycles. 

In an ART trial, 35.1% of live births were multiple births in women receiving GONAL-F RFF 75 IU.  The rate of multiple births is dependent on the number of embryos transferred.  Advise the woman and her partner of the potential risk of multi-fetal gestation and birth before beginning therapy with GONAL-F RFF 75 IU.

Embryofetal Toxicity
The incidence of congenital malformations (birth defects) after some Assisted Reproductive Technology [(ART) specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception.  This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI.  There is no evidence that the use of gonadotropins during IVF or ICSI is associated with an increased risk of congenital malformations.

Ectopic Pregnancy
Since infertile women undergoing ART often have tubal abnormalities, the incidence of ectopic pregnancy may be increased in women who become pregnant as a result of ART.  Advise women who become pregnant following ART and have: abdominal/pelvic pain (particularly on one side); shoulder, neck or rectal pain; and nausea and vomiting to seek immediate medical attention.  Confirm the presence of an intrauterine pregnancy early by β-hCG testing and transvaginal ultrasound.

Spontaneous Abortion
The risk of spontaneous abortion (miscarriage) is increased with gonadotropin products, including GONAL-F RFF 75 IU.  However, causality has not been established.  The increased risk may be a factor of the underlying infertility.

Ovarian Neoplasms
There have been infrequent reports of ovarian neoplasms, both benign and malignant, in women who have had multiple drug therapy for controlled ovarian stimulation, however, a causal relationship has not been established.

Laboratory Tests
In most instances, treatment of women with GONAL-F RFF 75 IU results only in follicular recruitment and development.  In the absence of an endogenous LH surge, hCG is given to trigger ovulation when monitoring of the patient indicates that sufficient follicular development has occurred.  This may be estimated by ultrasound alone or in combination with measurement of serum estradiol concentrations.  The combination of both ultrasound and serum estradiol measurement are useful for monitoring follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement and minimizing the risk of the Ovarian Hyperstimulation Syndrome and multiple gestation.  

 

ADVERSE REACTIONS:

The most common adverse reactions (≥2%) in ovulation induction (OI) include: headache, abdominal pain, ovarian hyperstimulation, injection site pain, nausea, flatulence, diarrhea, ovarian cyst, and injection site inflammation. The most common adverse reactions (≥2%) in ART include: abdominal pain, headache, abdomen enlarged, injection site bruising, nausea, injection site pain, ovarian hyperstimulation, injection site inflammation, injection site reaction, and injection site edema.
 

SPECIFIC POPULATIONS:

Pregnancy: GONAL-F RFF 75 IU is not indicated in pregnant women. There is no human data that the use of gonadotropins (including GONAL-F RFF 75 IU), alone or as part of IVF or ICSI cycles, increases the risk of congenital malformations. The risk of spontaneous abortion (miscarriage) is increased in women who have used gonadotropins products (including GONAL-F RFF 75 IU) to achieve pregnancy.

Lactation: There are no data on the presence of GONAL-F RFF 75 IU in human milk, the effects on the breastfed infant, or the effects on milk production.  Because the secretion of prolactin during lactation can result in inadequate response to ovarian stimulation, advise women not to breast feed during treatment with GONAL-F RFF 75 IU.

Females and Males of Reproductive Potential:  Because GONAL-F RFF 75 IU is not indicated in pregnant women, verify a negative pregnancy test before administering GONAL-F RFF 75 IU to a woman.

Pediatric use: Safety and effectiveness in pediatric patients have not been established.

Geriatric use: Safety and effectiveness of GONAL-F RFF in postmenopausal women have not been established and it is not indicated in this population.

 

PATIENT COUNSELING INFORMATION:

Instruct women on the correct usage and dosing of GONAL-F RFF 75 IU.  Instruct women to reconstitute one or more vials of GONAL-F RFF 75 IU using 1 mL sterile diluent and the 18G 1-1/2” pink mixing needle provided.  Instruct women to safely remove mixing needle and replace with 29G ½” needle for injection.  Caution women not to change the dosage or the schedule of administration unless she is told to do so by her healthcare provider. 

Prior to beginning therapy with GONAL-F RFF 75 IU, inform women about the time commitment and monitoring procedures necessary for treatment.

Inform the woman that if she misses or forgets to take a dose of GONAL-F RFF 75 IU, she should not double the next dose and should call her healthcare provider for further dosing instructions.

For more information, please see the full Prescribing Information and Instructions for Use for GONAL-F RFF 75 IU.

Indications and Usage:

  • Induction of ovulation and pregnancy in the oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure
  • Development of multiple follicles in ovulatory infertile women as part of an Assisted Reproductive Technology (ART) cycle.

 

RFF = revised formulation female.

 

You are leaving our website.

This link will take you to a website for which our Privacy Policy and Legal Statement may not apply. EMD Serono has no control over the contents and policies of third-party sites or resources, and accepts no responsibility for them or for any loss or damage that may arise from your use of them. Please review the Privacy Policy and Legal Statement for every website you visit.

Welcome to EMDSeronoFertility.com

      

I am a Healthcare Provider

 

 

 

I am a Patient

 

 

LEARN MORE